Tumor growth inhibition by intratumoral inoculation of defective herpes simplex virus vectors expressing granulocyte - Macrophage colony-stimulating factor

70Citations
Citations of this article
49Readers
Mendeley users who have this article in their library.

Abstract

To evaluate the potential of defective herpes simplex virus (HSV) amplicon vectors as in vivo cytokine gene transfer vehicles for active immunotherapy, we generated a defective HSV vector that encodes the murine granulocyte - macrophage colony-stimulating factor (GM-CSF) gene, using a replication-defective HSV as helper virus. A variety of murine tumor cell lines were efficiently infected in vitro with the defective GM-CSF vector (dvGM), and this led to the synthesis and secretion of murine GM-CSF. In an established bilateral subcutaneous tumor model with Harding-Passey murine melanoma, unilateral intratumoral inoculation of dvGM significantly inhibited tumor growth of both the inoculated and noninoculated contralateral tumors. This tumor inhibition was dose-dependent and resulted in increased survival of the dvGM-treated mice. Inoculation of a lacZ-expressing defective vector had no effect on tumor growth. We conclude that this defective HSV vector system offers an effective method for cytokine gene delivery in vivo and that GM-CSF expression in tumors has antitumor activity.

Cite

CITATION STYLE

APA

Toda, M., Martuza, R. L., & Rabkin, S. D. (2000). Tumor growth inhibition by intratumoral inoculation of defective herpes simplex virus vectors expressing granulocyte - Macrophage colony-stimulating factor. Molecular Therapy, 2(4), 324–329. https://doi.org/10.1006/mthe.2000.0130

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free